Public Lecture on Holistic Management of East Coast Fever (theilerosis) by: Prof. Nick Mchardy

Event Date
Friday, 6 July 2018 - 2:00pm
Event Info

Insight on use of pavaquone and Bupavaquone

Dr McHardy is a farmer’s son.  His father was manager of the Petworth (UK) herd of Sussex cattle, exporting many bulls to Southern and Eastern African countries from 1960-1980.  Now semi-retired, Dr McHardy visits African and Middle Eastern countries frequently for Bimeda’s product support and technical training programmes, principally on the control of tick-borne diseases.

He discovered the activity of imidocarb against anaplasmosis while working at the Wellcome Lab. in Kenya and led the development of Imizol (1973) to treat anaplasmosis and babesiosis.  He discovered and developed the first drug, parvaquone (Clexon, 1984, Parvexon, 1998), to treat East Coast fever (ECF) and Corridor Disease (CD), then buparvaquone (Butalex, 1993, Buparvex, 2002) and Parvexon Plus (parvaquone + frusemide, 2003) for advanced cases of ECF and CD.

Led the development of TeatSeal / Orbeseal, the leading non-antibiotic product for the prevention of mastitis in dry cows.  Developed Bimeda’s tick-transmitted diseases product range, based on parvaquone, buparvaquone and imidocarb.

Now semi-retired, he visits African countries frequently for Bimeda’s product support and training programmes, principally on the control of tick-borne diseases, and is involved in the development of new products, particularly for tick-transmitted diseases.

 

Event Venue
Media Hall, COVAB
Category by Unit
College of Veterinary Medicine, animal resources and bio-security
Contact Info
Contact Info: 
deansvar@covab.mak.ac.ug, bampa2008@gmail.com